Correlation analysis of atrial natriuretic peptide concentration, echocardiographic left atrial and left ventricular dimensions, and renal function parameters in patients after permanent pacemaker implantation

Cardiology Journal

Volumn 16, Issue 2, 2009, Pages 157-163

  Sielski, Janusz ^a   Janion, Marianna ^a   Gawor, Zenon ^b   Ciuraszkiewicz, Katarzyna ^a   Sielska, Maria Rebeka ^b  

^a Regional District Hospital   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

ANP; Correlation analysis; VVI and DDD pacing

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; CONTROLLED STUDY; CREATININE CLEARANCE; FOUR DIMENSIONAL ECHOCARDIOGRAPHY; HEART ATRIUM CONTRACTION; HEART ATRIUM FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE PACING; HEART VENTRICLE SIZE; HUMAN; IMAGE DISPLAY; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; TRANSTHORACIC ECHOCARDIOGRAPHY; BLOOD; CASE CONTROL STUDY; DOWN REGULATION; ECHOGRAPHY; HEART ATRIUM; HEART BLOCK; HEART FAILURE; HEART VENTRICLE; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DOWN-REGULATION; HEART ATRIA; HEART BLOCK; HEART FAILURE; HEART VENTRICLES; HUMANS; KIDNEY; MIDDLE AGED; PACEMAKER, ARTIFICIAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 66349120272     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kisch B. Electron microscopy of the atrium of the rat. I Guinea pig. Exp Med Surg, 1956; 11: 99.
2. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci, 1981; 28: 89-94.
3. Irzmański R, Rózalski S, Pawlicki L. Peptydy natriuretyczne w chorobach układu krażenia. Kardiol Pol, 2000; 53: 44-48.
4. Wilkins MR, Redondo J, Brown LA. The natriuretic peptide family. Lancet, 1997; 349: 1307-1310.
5. Cho KW, Seul KH, Kim SH, Seul KM, Koh GY. Atrial pressure, distension and pacing frequency in ANP secretion in isolated perfused rabbit atria. Am J Physiol, 1991; 260: R39-R46.
6. Greenvald JE, Apkon M, Hruska KA, Needelman P. Stretch - induced atriopeptin secretion in the isolated rat myocyte and it is negative modulation by calcium. J Clin Invest, 1989; 83: 1061-1065.
7. Haloui M, Arnal JF, Pham I, Gonzalez W, Lyoussi B, Michael JB. Functional compartmentation of the endocrine action of cardiac natriuretic peptides. Ann Endocrinol, 2000; 61: 32-40.
8. Wada A, Tsutamoto T, Matsuda Y, Kinoshita M. Cardiorenal and neurohormonal effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonists for guanylate cyclase-coupled receptors. Circulation, 1994; 93: 2232-2240.
9. Tabbibizar R, Maisel A. The impact of B-type natriuretic peptide levels on the diagnoses and management of congestive heart failure. Curr Opin Cardiol, 2002; 17: 340-345.
10. Tsutamodo T, Wada A, Maeda K et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Circulation 1997; 96: 509-519.
11. Tsutamodo T, Wada A, Maeda K et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur Heart J, 1999; 20: 1799-1807.
12. Yu CM, Sanderson JE. Plasma brain natriuretic peptide: An independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail, 1999; 1: 59-65.
13. Barold S, Zipes DP. Cardiac pacemakers and antiarrhythmic devices. In: Braunwald E. ed. Heart diseases. W.B. Saunders Co., Philadelphia 1992: 726.
14. Światecka G. ed. Wskazania do stałej stymulacji serca. W: Standardy postepowania w elektroterapii serca. Kardiol Pol, 1999; 50 (supl. 1): 5-17.
15. Gillis AM. Pacing to prevent atrial fibrillation. Cardiol Clin, 2000; 18: 25.
16. Amersham Human ANP (125) radioimmunoassay system with Amerlex-M™. Magnetic separation. Amersham International plc Amersham UK.
17. Irzmański R, Barylski M, Banach M et al. The concentration of atrial and brain natriuretic peptide in patients with idiopathic hypertension. Med Sci Monit, 2007; 10: CR449-CR456.
18. Irzmański R, Banach M, Piechota M, Kowalski J, Cierniewski C, Pawlicki L. Atrial and brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension: the dependence on the selected morphological parameters. Clin Exp Hypertens, 2007; 29: 149-164.
19. Hayashi Y, Ohtani M, Sawa Y, Hiraishi T, Kobayashi Y, Matsuda H. Left atrial diameter is a simple indicator of a deficiency in atrial natriuretic peptide secretion in patients with mitral stenosis: Efficacy of postoperative supplementation with synthetic human alpha-atrial natriuretic peptide. J Cardiovasc Pharmacol, 2004; 12: 709-717.
20. Tietz NW. Fundamentals of clinical chemistry. W.B. Saunders Co., Philadelphia 1987.
21. Stanisz A. Przystepny kurs statystyki w oparciu o program Statistica PL na przykładach medycyny. StatSoft Polska, Kraków 1998.
22. Eriksson SV, Caidahal K, Hall C, Eneroth P, Offstad J. Atrial natriuretic peptide ANP (1-98) and ANP (99-126) in patients with several congestive heart failure: relation to echocardiographic measurement. A subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). J Card Fail, 1995; 1: 109-116.